International guidelines allow for use of a short-term cancer bioassay (twenty-six weeks) in transgenic mice as a substitute for one of the two required long-term rodent bioassays in the preclinical safety evaluation of pharmaceuticals. The two models that have gained the widest acceptance by sponsors and regulatory authorities are the CB6F1-RasH2 mouse hemizygous for a human H-ras transgene and the B6.129N5-Trp53 mouse heterozygous for a p53 null allele. The p53 þ/À model is of particular value for compounds with residual concern that genotoxic activity may contribute to tumorigenesis. The rasH2 model is an appropriate alternative without regard to evidence of genotoxic potential. Since results from a short-term bioassay can be obtained relatively early in drug development, there is the potential for more timely assessment of cancer risk for individuals in longterm clinical trials. Use of these models in preclinical safety evaluation also significantly reduces animal use, time, and manpower. Preliminary findings indicate that prediction of two-year rat bioassay outcomes based on data from chronic rat toxicity studies, together with early assessment of carcinogenic potential in short-term transgenic models, may have the potential to increase the timeliness and efficiency of strategies for the identification of human carcinogenic hazards.
INTRODUCTION
The limitations and disadvantages of the traditional paradigm of testing in two long-term rodent bioassays to evaluate the carcinogenic potential of pharmaceuticals are well known and include the large number of animals required (!1,000), the significant time (3þ years) and expense (>$2,000,000) involved, the preponderance of species-specific responses that result, and the difficulty in extrapolating for effects seen at maximum tolerated doses to lower levels of human exposure. In addition, the results often do not contribute to a mechanistic understanding of effects, and extensive follow-up studies may be required to determine mode of action and to better understand the potential for human tumorigenic effects. There is also increasing societal interest in reducing the use of animals in testing.
The possibility of using alternative short-term carcinogenicity testing models employing transgenic mice as a substitute for a second two-year rodent bioassay in pharmaceutical testing was introduced in 1996 with the drafting of a new International Conference on Harmonization (ICH) guidance (S1B) on testing for carcinogenicity of pharmaceuticals (Contrera and DeGeorge 1998; International Conference on Harmonization 1998; Schwetz and Gaylor 1998; Tennant et al. 1999) . The S1B working group found, after an extensive review of available data on the carcinogenicity testing of pharmaceuticals and the regulatory decisions made based on the data, that there was little if any evidence that the additional data provided by a second long-term bioassay in the mouse had influenced regulatory decision making for new drug applications. Although consideration was given to reducing the requirement to one long-term bioassay in the most appropriate species (usually the rat), the S1B working group ultimately decided to preserve the standard of testing in two species but allow for the use of alternative models, such as short-term assays in transgenic mice, that might improve the utility, mechanistic understanding, and/or human relevance of the results obtained in a second in vivo bioassay. The new S1B guideline places the burden of proof on the sponsor to provide a scientific rationale for why a proposed alternative model might provide new information on the compound that would not otherwise be obtained from a second two-year bioassay.
SHORT-TERM TRANSGENIC BIOASSAY MODELS-IN PURSUIT OF A BETTER APPROACH
The discovery and cloning of oncogenes and tumorsuppressor genes in the 1980s and early 1990s and the rapid development of the technologies to create transgenic mice overexpressing or underexpressing these critical target genes in cancer development provided the tools to toxicologists to begin to leverage the growing knowledge base of molecular mechanisms underlying human cancer in the development of new carcinogenicity test models. A vision began to take shape of in vivo bioassays with transgenic mouse models that are engineered for accelerated tumorigenesis by activation of oncogenes (ras, myc) or inactivation of tumor suppressor genes of known importance in human cancer, have lower spontaneous background incidence of common age-related tumors at study end point, and are susceptible to chemically-induced acceleration of carcinogenesis. The expectations were that these models would (1) provide opportunities to understand mechanisms of carcinogenesis, (2) respond more selectively to known human carcinogens, and (3) significantly reduce the number of animals, time, and costs involved in carcinogenicity testing.
Interest in specific transgenic mouse models as potential test strains for chemical carcinogenicity testing emerged in the early 1990s with the initial publications on the characteristics of ras oncogene-bearing models, rasH2 (Ando et al. 1992; Saitoh et al. 1990 ) and Tg.AC (Leder et al. 1990; Spalding et al. 1993) , and the p53 þ/À tumor suppressor gene knockout models (Donehower et al. 1992; Harvey et al. 1993a Harvey et al. , 1993b Harvey et al. , 1995 . The United States (U.S.) National Institute of Environmental Health Sciences (NIEHS) took the lead in the United States, with studies exploring the utility of mouse mammary tumor virus promoter vectors containing myc, neu, and ras oncogenes ). In Europe, researchers at the Netherlands Cancer Institute were developing immunoglobulin enhancer-driven c-myc and pim-1 oncogene models of lymphoid malignancy (Adams et al. 1985; Breuer et al. 1989; , and the National Institute for Public Health and the Environment (RIVM) developed the XPA À/À knockout model with a DNA repair-deficient phenotype (de Vries et al. 1995; de Vries and van Steeg 1996; Berg et al. 1997; deVries et al. 1997) . In Japan, the Central Institute for Experimental Animals (CIEA) and collaborators undertook an extensive series of validation studies with the rasH2 model (Yamamoto et al. 1996; Yamamoto et al. 1997; Mitsumori et al. 1997; Mitsumori et al. 1998; Yamamoto, Urano, Koizumi et al. 1998; . Initial evaluations of the sensitivity of these models to known carcinogens were promising (Harvey et al. 1993; Kemp, Wheldon, and Balmain 1994; Spalding et al. 1993; Yamamoto et al. 1996) but indicated the models with increased susceptibility to tumors in a broad range of tissue would be preferred over tissue-specific models such as the MMTV vector models of mammary tumorigenesis ) and the Eu-pim-1 model of lymphoid malignancies (Storer et al. 1995) .
Although these exploratory studies of the suitability of transgenic models for accelerated carcinogenicity testing and the draft ICH S1B guideline opened the door for substantial innovation in the manner in which carcinogenicity testing and risk assessment was conducted for pharmaceuticals, the completion of an international collaborative effort led by the International Life Sciences Institute's (ILSI) Health and Environmental Sciences Institute (HESI) to further evaluate the responses of the candidate new models was required before several assays gained wider acceptance by industry, academics, and the regulatory community. The ILSI/HESI Alternatives to Carcinogenicity Testing project, initiated in 1996, coordinated the testing of up to twenty-one well-characterized, nonproprietary compounds, mostly pharmaceuticals, in six transgenic models (rasH2, p53 þ/À , Tg.AC oral, Tg.AC dermal, XPA À/À , and XPA À/À /p53 þ/À ) and in the neonatal mouse model with oral administration. The five-year ILSI effort concluded in 2001 with presentations of the results for the models at an international workshop in Washington, D.C. (Robinson and MacDonald 2001) , which included overviews of the nature of the models (French et al. 2001a; Tamaoki 2001; Tennant et al. 2001; van Steeg et al. 2001) , overall results for each model McClain et al. 2001; Storer et al. 2001; Usui et al. 2001; van Kriejl et al. 2001) , and critical perspectives of industry and academic experts on the outcome of the project (Ashby 2001; Cohen 2001) .
The general consensus that emerged from the workshop (Ashby 2001; Cohen 2001) was that the ILSI ACT project had succeeded in providing a solid foundation and database for further development, evaluation, and deployment of the models, even though they proved to be less than 100% accurate in prediction of human carcinogenic potential. Although the models clearly held promise as accelerated carcinogenicity assays, certain classes of known rodent carcinogens considered not to pose a risk to humans tested negative in these models. These results were considered by most to be an advantage of the transgenic models, but the 2001, workshop consensus on this point was incomplete. Nevertheless, the specific advantages cited were the lower cost and smaller number of animals required, the lesser degree of sensitivity to nongenotoxic rodent carcinogens, and the apparent greater specificity in predicting actual carcinogenic hazard to humans. It was suggested that results from these assays-in conjunction with data from other sources such as structure activity, genotoxicity, rat bioassay results, and other biological information-could contribute to the overall evaluation of carcinogenic potential and a weight-of-evidence approach to human risk assessment. Disadvantages and caveats noted included the apparent limited usefulness of the models for quantitative risk assessment, and just as for the two-year assays, for predicting target organ specificity for human carcinogenesis. In addition, it was noted that specific models such as the Tg.AC assays lacked a clear indication of mechanistic relevance, relying mostly on empirical correlations, and that current understanding of mechanisms of carcinogenesis should be integrated into the evaluation of new bioassay models. Looking forward, it was thought that a mechanism by which new models can be adopted or rejected for use in the routine bioassay, as well as more agreement on a standard list of calibration chemicals, optimal bioassay group sizes, statistical methods, and exposure periods, was needed. Some of these issues were addressed in a subsequent ILSI ACT-sponsored conference (MacDonald et al. 2004 ).
52
STORER ET AL. TOXICOLOGIC PATHOLOGY There were a number of important technical lessons learned from the development and execution of the ILSI ACT project protocols for the assays. Although six-month duration assays appeared to be near optimal for the rasH2 (Morton et al. 2002) and Tg.AC models, data for the XPA À/À models supported a longer (nine-month duration) study. Although six months was deemed sufficient for the p53 þ/À model, data from a non-ILSI-sponsored study with benzene (Boley et al. 2000; Donehower 1996 ) that lacked a scheduled six-month terminal necropsy contributed to concerns that a study of longer duration might be possible for the p53 þ/À model. The inclusion of positive control compounds in each assay proved very valuable, demonstrating consistency in model responses over time and between laboratories. Positive controls as a quality control check on stability of the genotype also enabled the detection of a nonresponder genotype that arose in the Tg.AC breeding population Thompson, Rosenzweig, and Sistare 1998; Thompson et al. 2001) , demonstrating that at a minimum, confirmation of genotype would be required if assays were allowed to be conducted without a concurrent positive control. The ILSI results also showed that the models were in general not overly sensitive and prone to false positives, but rather the achievement of maximum tolerated doses maximized detection of compounds with carcinogenic potential. Pathology data analysis for several compounds tested in different models indicated that increased incidences of hyperplastic and preneoplastic lesions could support a conclusion that a study was positive when rare tumors in the same target tissue, on a continuum with the non-neoplastic proliferative lesions, were observed at increased frequency that did not achieve statistical significance. Finally, the inclusion of wild-type control and high-dose-treated groups was informative in several cases, providing additional examples of tumor responses in p53 þ/À mice that were, as expected, accelerated in the transgenic as compared to the wild type for a genotoxic carcinogen cyclophosphamide, but not for a nongenotoxic carcinogen, cyclosporine A (Storer et al. 2001) .
The ISLI ACT-sponsored studies and other published studies revealed deficiencies in the performance of individual short-term transgenic carcinogenicity models as stand-alone assays for the detection of tumorigenic activity of concern for human cancer risk assessment. However, subsequent analyses of the performance of the p53 þ/À , Tg.AC, rasH2, and XPA À/À (and/or XPA À/À /p53 þ/À ) for a larger data set (fifty-nine, sixty-two, fifty-one, and eighteen compounds tested, respectively) provided further support for their use in the type of overall test strategy established by the ICH S1B guideline models (de Vries et al. 2004; Pritchard et al. 2003) . Using the International Agency for Research on Cancer (IARC) and NTP Report on Carcinogens (ROC) evaluations of human carcinogenic potential of ninety-nine test chemicals, these authors reported (Table 1 ) that individual transgenic models correctly predicted carcinogenic activity for 74% to 83% of the chemicals, and for up to 85% of the chemicals using a strategy that factored in underlying mechanisms of model susceptibility, for example, using the p53 þ/À model only for genotoxic chemicals (twenty-two of twenty-six detected). Although as stand-alone assays, the transgenics failed to detect a number of known or probable human carcinogens, mixed strategies using a rat bioassay in conjunction with a transgenic (for example, using p53 þ/À for genotoxic compounds and rasH2 for nongenotoxic compounds) had an overall predictivity accuracy of 85%, detected all known or probable human carcinogens, and had a fairly low false-positive rate (eight of fifty-three, or 15%). This finding indicated a significant improvement in specificity over results for the NTP two-year bioassay testing paradigm in two species for the same compound set where the overall accuracy (64%) was pulled down by a higher rate of false-positive results (twenty-three of sixty-six, or 35%) for the IARC Category 3 compounds (assumed to be human noncarcinogens). Examples of these false-positive results include phenobarbital and sulfamethoxazole, which can induce metabolism and decrease production respectively of endogenous thyroid hormone to result in an indirect hormonal feedback stimulation of thyroid tumors in a rodent-specific manner and reserpine; haloperidol; and chlorpromazine, which can block pituitary dopamine receptors to elevate prolactin secretion, resulting in an indirect hormonal feedback stimulation of mammary tumors in a rodent-specific manner. These compounds all tested negative in the rasH2 model (Table 2) and are considered rodent bioassay false positives for prediction of human carcinogenicity.
CURRENT REGULATORY STATUS OF THE MODELS FOR DRUG SAFETY TESTING
The ICH S1B guideline first approved in 1996 remains in effect and was not included in the most recent round of Assuming most of these concerning results are from in vitro clastogenicity assays, it would be very helpful to conduct a detailed review of these data to facilitate an evaluation of the question of whether the p53 þ/À model is insensitive or if the in vitro clastogenicity assays are prone to false positives and/or are associated with cytotoxicity and do not accurately predict in vivo clastogenicity. An alternative hypothesis that the clastogenic events observed do not translate into in vivo clastogenicity or further result in carcinogenesis could be explored. In the European Union, regulatory spokespersons have indicated that in their view, the data for the transgenic models do not suggest that any one model may be more appropriate for a compound class than another, and in general, they have supported the concept that data from the models can add value to the risk assessment process, even though a single long-term bioassay in the most appropriate species has been suggested to be sufficient in their view for the assessment of carcinogenic potential. The regulatory consensus on the use of the dermal Tg.AC model appears to be that it may have value only in the assessment of pharmaceuticals intended for dermal administration, but a high percentage of compounds with positive results submitted, confounding effects of inflammation, and uncertainty on how to handle positive results when the two-year bioassay data are negative have created uncertainty as to the value of the model in pharmaceutical risk assessment. Preliminary data from an evaluation of the rasH2 model as a candidate for a short-term dermal carcinogenicity assay appear promising, and further evaluation of the model for this application may be warranted (Paranjpe, Wenk, and Smith 2008) . Tennant et al. 1999; j French, Lacks, et al. 2001a; k Yamamoto et al. 2000; l Dunnick, et al. 1997; m Koujitani, et al. 2000; n Ozaki et al. 1998; Jiang et al. 1999; p Jiang et al. 2001; q Harvey et al, 1993; Kemp et al. 1993; s Torti et al. 2001; t Stoll et al. 1999; u Carmichael, Debruyne, and Bigot-Lasserre 2000; v Pritchard et al. 2003; w Jin et al. 2007 . Vol. 38, No. 1, 2010 As regulatory and industry experience with the use of transgenics in carcinogenicity testing has grown, there appears to be a scientific and regulatory consensus that the models have added value in drug safety testing and risk assessment for the carcinogenicity of pharmaceuticals. In some cases, it appears the pharmaceutical companies have been slow to adopt these assays for routine use, the reluctance apparently owing to several factors. The absence of large internal historical control databases for spontaneous lesion incidence is one factor, with companies in some cases preferring to use the two-year bioassay models for which the years of experience and accumulated historical control data contribute to the ''devil we know'' perspective. The issue with limited internal historical control data can, however, be mitigated by outsourcing assays to contract research organizations (CROs) with significant accumulated data, provided that their experience with control data is not ''owned'' by the individual companies sourcing the studies. In addition, confidence in the rigor of the genetic toxicology test batteries and the available strategies for mechanistic follow-up of in vitro positive results has limited enthusiasm for the conduct of p53 þ/À assays where the rationale for the assays is to obtain further weight of evidence of a compound's potential to act as a genotoxic carcinogen. Another factor that may have contributed to a reluctance to use these models is the perception that the models would be oversensitive and prone to false positives, which would then become significant issues with respect to any further development of the compound. Based on recent data overviews presented by regulatory agency representatives, these are still valid concerns for the Tg.AC model, but such concerns do not appear to be warranted for the p53 þ/À and rasH2 models.
A case can now be made for broader use of the short-term transgenic carcinogenicity testing models in drug safety assessment (Table 3) . As pharmaceutical compound development teams ponder preclinical and clinical development strategies and timelines, any toxicologic, pharmacologic, or mechanistic data that raise any concern about carcinogenic potential is of paramount importance. This holds true not only for ultimate drug approvability, but also for the safety of patients enrolled in the progressively larger and longer-duration clinical trials that need to be conducted as compounds move into phase II and phase III clinical development. Early conduct of a short-term, transgenic assay that results in identification of significant carcinogenic potential will, in most cases, lead to early termination of a program, limiting the duration and number of patients who have been exposed, and enabling earlier redirection of costly late-stage resources to more promising programs. When negative, the earlier assessment of carcinogenic potential builds confidence for the sponsor, patients, and physicians that the weight of evidence does not indicate significant carcinogenic potential and that the benefit-risk assessment can be weighted toward expanded-duration clinical trials with larger enrolled patient populations, potentially accelerating patient access to improved therapies for unmet medical needs.
In certain cases, the use of transgenic carcinogenicity testing models can also provide early insight into mechanisms of carcinogenesis. A positive p53 þ/À assay, especially when followup testing of tumors for loss of heterozygosity for the p53 þ allele, as in the case of phenolphthalein and benzene (Dunnick et al. 1997; French et al. 2001a) , confirms an in vivo cytogenetic effect in the tumor cells from treated mice. In the case of suspected cases of nongenotoxic, receptor-mediated mechanisms of carcinogenesis in two-year bioassays, the availability of knockout mice for the putative target receptor can enable confirmation of the role of the receptor in the pharmacodynamic TABLE 3.-Pros and cons to the selection of a six-month p53 þ/À or rasH2 mouse versus a standard two-year mouse carcinogenicity test.
Advantages to the 6-month transgenic mouse assay 1. Earlier insight to pharmaceutical carcinogenic potential -enhanced overall clinical trial safety -earlier re-direction of sponsors away from non-viable to more viable test candidates -earlier resolution of hypothetical carcinogenicity concerns -earlier trigger for investigative studies to understand cause for any human concern 2. Can provide some mode-of-action understanding of positive findings 3. May enable adoption of a strategy that eliminates the 2-yr rat carcinogenicity testing timeline for clear noncarcinogens 4. Reduction and refinement of animal use 5. Significant savings in overall testing costs -reduced test article demands -animal husbandry costs for 6 month vs 2 years of study activities -histopathology assessment costs reduced with fewer animal numbers -test facility space requirement demands are reduced and allow greater scheduling flexibility 6. Reduced chance for a rodent-specific and human irrelevant false positive outcome Advantages of the two-year mouse carcinogenicity assay 1. Large accumulated historical control databases for spontaneous lesion incidence -less risk that a single spontaneous tumor in one HD study animal will raise a concern 2. No expectation that a positive control study arm be conducted -no risk for incidental contamination of study animals with a known carcinogen 3. Acceptable for top doses which exceed 25X human exposure and do not require MTD 56 STORER ET AL. TOXICOLOGIC PATHOLOGY mechanism, and in the case of the PPARa receptor knockout and human gene knock-in models, can even contribute to an understanding at the molecular level of species differences in susceptibility. In this manner, additional testing in transgenics other than accepted rasH2 or p53 þ/À models ultimately contributed to a better understanding of the relevance of positive findings for PPARa agonists in the rasH2 model. In addition to their added value in providing earlier insight into carcinogenic potential and mechanisms, transgenic testing models can ultimately reduce the high costs of drug development. The assays themselves, although they have the higher up-front costs for the mice, ultimately yield significant savings in manpower because of their shorter duration (26 vs. 104 weeks) and the smaller number of animals required (*280 for a transgenic assay vs. !500 for a two-year bioassay). The reduced costs for test article materials, formulation, diet, and facility overhead all contribute to the significant overall cost savings associated with short-term transgenic assays. More importantly, earlier terminations of clinical programs for nonviable compounds could save tens of millions of dollars, and the earlier redirection of a development program to a viable candidate could ultimately yield hundreds of millions of dollars in revenue from the sales of a marketed product brought forward more quickly. Finally, the substitution of a short-term alternative bioassay with the smaller number of animals required contributes to the goals of reducing and refining animal use.
ISSUES WITH USE OF TRANSGENICS IN CURRENT TESTING PARADIGMS
As companies move toward broader use of the short-term transgenic models, careful consideration needs to be given to each potential candidate compound in terms of any causes for concern for carcinogenic potential that may lead to prioritizing the compound for accelerated carcinogenicity testing. For example, in the case of any borderline or equivocal findings in the genetic toxicology test results that leave the in vivo genotoxic potential of the compound in doubt, there may be sufficient residual concern to justify acceleration of carcinogenicity testing and use of the rasH2 or p53 þ/À model in place of the two-year mouse bioassay. Similarly, since almost all known human carcinogens identified to date appear to work by genotoxic, hormonal, or immunosuppression mechanisms, any evidence of hormonal or immunosuppressive effects, either as known pharmacodynamic effects of the compound or unanticipated off-target effects, would also be cause for concern and consideration of prioritization for accelerated carcinogenicity testing and use of a short-term transgenic model. Consideration also needs to be given to accelerating the start of the two-year rat bioassay and whether the full carcinogenicity data set may be desirable to have prior to enrolling large numbers of patients in phase III clinical trials. In this case, consideration of current data sets for predictive accuracy of six-and/or twelve-month rat chronic toxicity data for preneoplastic lesions for twoyear rat carcinogenicity outcomes may be instrumental in strategic decision making for triaging and resource allocation. In particular, for the large number of drugs in development for type 2 diabetes where expensive, longer-term phase III clinical trials to address cardiovascular safety may be required prior to marketing, earlier assessment of carcinogenic liabilities in a development candidate may be critical.
In evaluating compounds as candidates for the short-term alternative assays, regulatory authorities have indicated that further consideration may need to be given to compounds that may have concerns for carcinogenic activity of uncertain relevance to man. For example, nuclear receptor agonists in certain classes such as PPARa, g, and d, dual or pan agonists, and retinoids all have rodent carcinogenicity concerns, and earlier identification of issues for tumorigenic activity allow for earlier opportunities to initiate investigative follow-up action and strategic decisions. In this case, careful consideration needs to be given to the current status of evaluation of a model for novel classes. In the case of PPARa agonists, approval of a rasH2 assay will likely be allowed to meet regulatory testing guidelines and will also be informative with respect to compound activity, since three different PPARa agonists have been included in published results from the ILSI ACT project (Usui et al. 2001 ; see also Table 2 ). However, in the case of PPARg, ag, and d, or dual or pan agonists, although conduct of the rasH2 may still be informative and facilitate earlier internal decision making, assay results may not be acceptable to meet regulatory requirements if sufficient data are not available on the performance of the assay for the agonist class. This was the case with PPARg agonists, in which the human relevance of the species-specific hemangiosarcoma response in two-year mouse bioassays could not be dismissed and there were no data, until the recent publication of positive findings with troglitazone, to support the responsiveness of the model to this class (Jin et al. 2007) .
Confidence in the utility of the transgenics in flagging human relevant tumor responses is likely to continue to grow as further experience is gained. The recent controversy with respect to the human relevance of the clear thyroid C-cell tumorigenic response in both sexes of rats and mice with the GLP-1 agonist liraglutide will be an interesting case study. Since in the case of both Byetta (exenatide) and liraglutide, there was a response in rats (females only with Byetta), rats have a high background incidence of thyroid C-cell hyperplasia, and a mouse C-cell hyperplasia response was evident within six months in nontransgenic mice with liraglutide, applications for regulatory acceptance of rasH2 protocols for GLP-1 agonist testing may be more likely to be approved than was the case for PPARg agonists. In cases such as these, careful consideration of the available data for the pharmacodynamic mechanisms of a new class, the response of the rat, and any data on cell growth, differentiation, and cell survival signaling mechanisms in target tissue of concern may all influence a decision on moving forward with a strategy using a short-term transgenic model for internal decision making, to meet regulatory testing requirements, or both. Current indications are that the regulatory decisions will continue to be made on a case-by-case basis, as originally set forth in the 1996 ICH S1b guideline, in which the Vol. 38, No. 1, 2010 TG MICE IN DRUG CARCINOGENICITY TESTING burden of proof was placed on the sponsor to provide a rationale for the use of an alternative that could provide new data not otherwise available from a second, long-term bioassay.
A third category to consider in prioritizing compounds for accelerated testing in short-term models is compounds for which there is cause for concern about rodent carcinogenic activity not relevant to man or likely to demonstrate a threshold. Phenobarbital-like cytochrome p450 enzyme inducers, for example, might be expected to be positive in a two-year mouse bioassay, but negative in rasH2. In this case, an early rasH2 assay might not only be acceptable for regulatory filing, but also might avoid the situation of obtaining a positive mouse liver tumor response in a two-year bioassay not likely to be relevant to human risk, but that could negatively influence the label and market competitiveness of the product. Another common situation might be where early toxicity testing identifies the potential for organ-specific cytotoxic responses at maximum tolerated doses but with considerable safety margins relative to exposures at the maximum anticipated human dose. In such cases, concerns for regenerative proliferative responses promoting tumorigenesis at the requisite maximum tolerated doses in a transgenic model may mitigate toward choosing the traditional paradigm of two long-term bioassays conducted with acceptably high margins of exposure (>25Â) at the high dose but at doses considerably lower than an MTD associated with chronic organ toxicity.
When scientific considerations do not necessarily favor the choice of a short-term transgenic model or the two-year bioassay or suggest a significant cause for concern for tumorigenic activity, practical considerations may come into play that favor use of a short-term model. For example, an unexpected delay after initiating chronic rat studies might create a situation in which the required time for conduct of a fourteen-week mouse range-finding and two-year bioassay is rate limiting for development and Worldwide Marketing Authorization (WMA) filings. Alternatively, when issues with peak workloads and ongoing concurrent carcinogenicity studies that stress pathology, toxicology, and/or facility resource availability, the flexibility to initiate a six-month bioassay allowing study termination at an alternate time to balance workload may be attractive. Additionally, for lower-priority compounds, the opportunity to use a short-term model and delay initiation of the second in vivo carcinogenicity bioassay can help control drug development costs by limiting pre-investment in the more expensive two-year bioassay.
CURRENT PERSPECTIVES ON MODELING HUMAN CANCER IN MICE
Species, strain, and/or sex-specific responses in mice have often confounded the interpretation of two-year mouse bioassay results and increased the complexity of the deliberations by toxicologists of the relevance of the findings to human risk assessment. A current case in point is hemangiosarcoma induction in mice with nongenotoxic carcinogens such as the PPARg agonists, the synthetic retinoid fenretinide, or currently marketed products such as pregabalin, all of which exhibit a species-specific response (Cohen et al. 2009 ). Examples such as these undermine our confidence that carcinogenicity test results, in either two-year mouse bioassays or in the shortterm alternative assays in transgenic mice, are predictive of human carcinogenic potential. Notwithstanding the complex issues mouse carcinogenicity testing models present to toxicologists, basic cancer research has an ongoing love affair with transgenic mouse models of human cancer (Graeber and Sawyers 2005) . Using the myriad of new technologies available to manipulate gene expression in transgenics, researchers have found a high degree of conservation between mice and humans of many of the key transmembrane growth factor receptors, downstream intracellular signal transduction pathways, and modes of regulation of critical processes such as cell cycle progression, cell proliferation, cell differentiation, and cell death that when dysregulated, can lead to cancer. Mouse models of cancer have therefore proved invaluable in understanding central pathways involved in cancer development (Frese and Tuveson 2007) .
Fundamental species differences between mice and man remain, however (Anisimov, Ukraintseva, and Yashin 2005; Dennis 2006 ). The spectrum of common age-related neoplasms is very different, with a greater preponderance in mice of cancers such as lymphomas and sarcomas arising from mesenchymal tissues compared to humans, where epithelial tumors are more common. Extensive parallel experimentation with in vitro transformation of rodent and human fibroblast has revealed fundamental differences in telomere biology and the control of replicative senescence, which appear to explain the relative ease with which rodent cells can be immortalized. And studies of the minimum number of genetic alterations in key signaling pathways (ras) and cell cycle control genes (p53, Rb, myc, p16.ink4A, p19 ARF) have also shown that fewer changes appear to be required in mouse cells initiate and transform cells in tumorigenesis (Hahn and Weinberg 2002; Rangarajan and Weinberg 2003) .
These considerations suggest that some responses in ''humanized'' mouse models used in carcinogenicity testing may remain highly species and/or strain specific. A recent example of marked strain specificity is the target tissue response to urethane in the p53 and rasH2 models, in which it was shown that in the C57BL/6 background of the p53 model, the response was specific to the liver, with peliosis hepatitis induced in C57BL/6 and p53 wild-type mice and hemangioma in the p53 þ/À . In contrast, in the rasH2 model, the BALB/c contribution to the F1 hybrid background with C57BL/6 appeared to be the determinant of the target tissue switch to lung adenoma and spleen hemangioma responses (Ozaki et al. 2005) . Integrated application of current technologies may allow us to identify species-and strain-specific susceptibility factors and assess human relevance. For example, genomic and bioinformatic analyses of species and strain polymorphisms including single-nucleotide polymorphisms (SNPs), gene copy number variations, and endogenous retroviral elements, may yield associations with mouse species-and strain-specific responses. A recent bioinformatic search of the C57BL/6 58 STORER ET AL. TOXICOLOGIC PATHOLOGY genome found up to about 700 polymorphic intracisternal A particle (IAP) or ETnMusD endogenous retroviral elements or solo retroviral long-terminal repeats (LTRs) in gene introns that may contribute to gene expression changes in different mouse strains (Zhang et al. 2008) . The IAP and ETn/MusD elements are classes of retrotranposons in mice that may have very dramatic effects on gene expression at their site of insertion and are subject to nutritionally and xenobiotic-mediated epigenetic regulation (Dolinoy, Huang, and Jirtle 2007; Waterland and Jirtle 2003) . Many of the genes found to harbor an insertion of an IAP element within, or in close proximity ( 10 kb) to, gene borders are known to play important roles in the regulation of cell proliferation, the cell cycle, and cell death (Qin et al. forthcoming) . Transcriptomic analyses of gene expression alterations in tumors may also help identify key signaling pathways that are dysregulated in tumors induced in transgenic models (Jin et al. 2007; Lee et al. 2004) . When combined with epigenetic profiling and gene mutation analyses, integrated analyses of these data can enable mapping and identification of oncogenesignaling collaborations, as shown for human cancer (Cui et al. 2007) , and help inform our understanding of species similarities and differences in susceptibility to chemical carcinogenesis.
FUTURE ROLE OF TRANSGENICS IN CARCINOGENICITY TESTING OF PHARMACEUTICALS
With an emerging consensus that the transgenic models have added value for human cancer hazard identification in carcinogenicity testing of pharmaceuticals, several new initiatives to improve the accuracy and efficiency of carcinogenicity testing strategies have focused on the question of whether a lifetime bioassay in the rat is always necessary or whether the outcome of a two-year rat carcinogenicity study can be predicted with confidence based on data from thirteen-week (Jacobs 2005) or the six-and/or twelve-month chronic toxicity studies in rats (Jacobsen-Kram 2008; Reddy 2007) . Our initial approach (Reddy 2007) was to ask whether histopathologic lesions indicative of risk for neoplasia in a chronic study predict a two-year carcinogenic response. Specifically, is there a correlation between whole animal histopathologic evidence at six and/or twelve months and carcinogenesis after two years? The approach involved evaluation of results for seventy-nine compounds with closely matching doses (+25%) in six-and/ or twelve-month chronic toxicity studies and two-year rat carcinogenicity studies. The compounds assessed included fifty-seven drugs from the Leadscope database (primarily from publicly accessible NDA reviews of approved drugs) and twenty-two compounds with data from twenty-four paired studies conducted by Merck Safety Assessment. Preliminary results showed poor response correlation for tissue (site)-based tumor prediction based on histology ''positives'' (hyperplasia, hypertrophy, basophilic or eosinophilic foci or tumors) in that tissue. However, this finding may be irrelevant to the utility of the approach if there is a good correlation between the whole animal histopathologic evidence of these lesions in any tissue at six and twelve months and a positive finding at any site in the two-year carcinogenicity study. For the initial seventynine-compound Leadscope/Merck database, based on the histologic evidence as defined above, or lack thereof, there was 89% (thirty-four of thirty-eight) negative predictivity and 87% (twenty-six of thirty) test sensitivity (four false negatives). There were fifteen false positives, so positive predictivity was 63% (twenty-six of forty-one). The four false negatives (gabapentin, olanzapine, rosiglitazone, and sibutramine) all produced tumors resulting from proliferative or hormonal effects and are approved for non-life-threatening conditions, indicating a relatively low risk compared to the benefit. Based on this initial data set, a further analysis, sponsored by the PhRMA Preclinical Safety Leadership Committee (PSLC), is in progress with an expanded data set.
These data provided support for further evaluation of a more efficient carcinogenicity testing paradigm in the drug approval process. If an integrated assessment of the genetic toxicology test battery results, the chronic rat toxicity study histopathology on a whole-animal basis, and any evidence of hormonal perturbation in the chronic rat study does not identify any cause for concern, carcinogenicity bioassays for a particular compound could, after regulatory review and agreement as in the FDA CAC's Special Protocol Assessment process, be limited to a single short-term study in a transgenic model. Using criteria derived from these types of analyses as triggers for a requirement for a two-year rat carcinogenicity study could lead to a significant reduction in two-year rat carcinogenicity studies and in development time and costs if an early (phase II) carcinogenicity assessment conducted in a six-month transgenic mouse bioassay is used as the only specific in vivo carcinogenicity bioassay.
